港股異動丨歐舒丹(0973.HK)漲逾7% 半年少賺37.5%不派息 或加快美國等市場店鋪整合
格隆匯12月1日丨歐舒丹(0973.HK)漲逾7%,報17.54港元,股價創今年1月以來新高,總市值259億港元。

歐舒丹昨日公佈,截至2020年9月30日止六個月,該公司錄得銷售淨額約為6.17億歐元,同比下降15.2%。股東應占溢利約1561.3萬歐元,同比下降37.53%。每股盈利0.011歐元;不派息。
歐舒丹稱,下半年的營商環境仍充滿挑戰,集團正進行重組過程以加快轉型,可能導致全球9,000名員工中流失約300個職位。集團亦積極處理虧損領域,L’OCCITANE au Brésil及Melvita正進行重組,並可能加快美國等市場的店鋪整合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.